Marker Therapeutics, Inc. (MRKR)

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. In addition, the company is developing PolyStart, a proprietary nucleic acid-based antigen expression technology to enhance the ability of the immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Current Quote*
Last: $4.180
Change: -0.130
Book: $3.818
Volume: 111,545

As Of: 10/18 12:53 ET
*Quotes delayed by 20min.

Graphs for MRKR


3 Month Graph


6 Month Graph


1 Year Graph